Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Efficacy and Safety of ABP 501 Compared With Adalimumab in Subjects With Moderate to Severe Plaque Psoriasis
Brief Summary: The purpose of this research study is to compare the efficacy and safety of ABP 501 and adalimumab (HUMIRA®) in adults with plaque psoriasis.


Options:
A: Arm Label: ABP 501; Type: EXPERIMENTAL; Interventions: Biological: ABP 501 | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: ABP 501; Assigned to Arm(s): ABP 501
B: Arm Label: AIN457 150 mg - Fixed Interval (FI); Type: EXPERIMENTAL; Interventions: Drug: AIN457 150 mg, Drug: Placebo | Arm Label: AIN457 150 mg - Start of relapse (SoR); Type: EXPERIMENTAL; Interventions: Drug: AIN457 150 mg, Drug: Placebo | Arm Label: AIN457 300 mg - Fixed Interval (FI); Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Arm Label: AIN457 300 mg - Start of Relapse (SoR); Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg, Drug: Placebo | Arm Label: AIN457 300 mg - Open Label (OL); Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Intervention Type: DRUG; Name: AIN457 150 mg; Assigned to Arm(s): AIN457 150 mg - Fixed Interval (FI), AIN457 150 mg - Start of relapse (SoR) | Intervention Type: DRUG; Name: AIN457 300 mg; Assigned to Arm(s): AIN457 300 mg - Fixed Interval (FI), AIN457 300 mg - Open Label (OL), AIN457 300 mg - Start of Relapse (SoR) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): AIN457 150 mg - Fixed Interval (FI), AIN457 150 mg - Start of relapse (SoR), AIN457 300 mg - Start of Relapse (SoR)
C: Arm Label: 140 mg SC; Type: EXPERIMENTAL; Interventions: Drug: 140 mg SC | Arm Label: 70 mg SC; Type: EXPERIMENTAL; Interventions: Drug: 70 mg SC | Arm Label: 280 mg SC; Type: EXPERIMENTAL; Interventions: Drug: 280 mg SC | Arm Label: 210 mg SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg SC | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 70 mg SC; Assigned to Arm(s): 70 mg SC | Intervention Type: DRUG; Name: 210 mg SC; Assigned to Arm(s): 210 mg SC | Intervention Type: DRUG; Name: 140 mg SC; Assigned to Arm(s): 140 mg SC | Intervention Type: DRUG; Name: 280 mg SC; Assigned to Arm(s): 280 mg SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 200 mg, Drug: Matching Placebo | Arm Label: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 100 mg, Drug: Matching Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tildrakizumab 200 mg, Drug: Tildrakizumab 100 mg, Drug: Matching Placebo | Intervention Type: DRUG; Name: Tildrakizumab 200 mg; Assigned to Arm(s): Placebo, Tildrakizumab 200 mg | Intervention Type: DRUG; Name: Tildrakizumab 100 mg; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg, Tildrakizumab 200 mg

Answer: A